With the dynamic pace of change in pharma today, strong clinical data alone may no longer be enough to secure market leadership. Bringing clarity from complexity stakeholders process more information than ever means the window to inform understanding and drive choice is narrowing.
Positioning should help brands differentiate. In newer or evolving markets, it can help define how the category itself develops; shaping how stakeholders understand the unmet need, the treatment landscape, and the role a new therapy should play.
Yet many companies are still approach positioning too late, treating it as a downstream commercialization exercise rather than a strategic discipline that should shape development decisions from the beginning.
Why Positioning Gets Delayed
Across the industry, positioning often gets deprioritized in favor of more immediate demands: clinical execution, regulatory milestones, evidence generation, portfolio decisions, and launch readiness activities.
For emerging biopharma companies, this can stem from lean teams and limited resources. In larger organizations, it often comes from complexity; multiple stakeholders, competing priorities, and the assumption that positioning can be refined later once more data emerges.
We often hear teams say they are interested to see “how physicians will position the asset” once data emerges. Implicitly, this assumes the market will organically determine the product’s place in the treatment landscape.
However, waiting for the market to decide how your asset is perceived cedes control at precisely the moment when strategic clarity matters most. If you do not define the narrative early, competitors, investors, physicians, or payers often define it for you. The result is typically fragmented messaging, internal misalignment, and a product that struggles to establish a clear identity in a crowded field.
“Waiting for the market to decide how your asset is perceived cedes control at precisely the moment when strategic clarity matters most. If you do not define the narrative early, competitors, investors, physicians, or payers often define it for you.”
Creating DESIRE
At Lumanity, we pressure-test positioning through the DESIRE framework. Strong positioning should be:
| Element | What it Means |
|---|---|
| Distinct | Clearly differentiated versus competitors |
| Emotive | Connected to what stakeholders feel, not just what they think |
| Single-minded | Focused on a core idea rather than trying to claim everything |
| Insight-led | Grounded in genuine customer needs and behaviors |
| Resonant | Meaningful to the audiences that matter most: e.g., HCPs, patients, payers |
| Environment-aware | Built for the future market, not just today’s landscape |
This becomes increasingly important as therapeutic areas become more crowded and clinically sophisticated. In many markets, multiple products may ultimately demonstrate similar efficacy profiles. Positioning is what gives the competitive advantage and shapes the data to give meaning.
The strongest brands create a mental shortcut. They become associated with a specific idea, patient type, unmet need, or clinical value proposition, in a way competitors cannot easily replicate.
Positioning Early Enough to Influence Strategy
One of the biggest misconceptions in pharma positioning is that teams need mature clinical data before meaningful positioning work can begin. However, early positioning decisions can directly influence development strategy, evidence generation priorities, target patient definitions, trial differentiation, and future commercial narrative. Early positioning work should include:
- Aspirational target product profile (TPP) development
- Future market and treatment paradigm modeling
- Competitive whitespace assessment
- Cross-functional alignment across clinical, commercial, medical, payer and patient perspectives
More importantly, positioning should not be built around today’s market alone. Most assets launch into environments that look materially different from the ones they entered during early development. Teams must anticipate:
- How standards of care may evolve
- Which competitors may emerge
- How biomarker adoption could shift
- What future stakeholder expectations may become
Positioning that only works for today’s market may already be obsolete by launch.
Ruthless Prioritization Wins
One of the most common positioning mistakes is trying to own too many messages simultaneously. Teams understandably want to highlight every potential strength: Efficacy, safety, convenience, tolerability, dosing, patient experience and cost implications.
As more stakeholders contribute to positioning over time, brands often add messages rather than refine them. The result is often a broader story that feels less distinct. Positioning weakens as it expands. The most effective brands are anchored in one defining idea.
That does not mean the product only delivers one benefit. It means the market retains one primary reason the asset matters and uses that idea as a shortcut for how to think about it. Getting to that level of clarity requires trade-offs and real discipline: choosing what not to lead with, and deprioritizing good messages in service of the one message most likely to create durable differentiation. In positioning, clarity almost always beats completeness.
Data Cannot Speak for Itself
Clinical data does not automatically create market leadership. In competitive categories, products with strong data can still struggle commercially if stakeholders do not immediately understand:
- Where the product fits
- Why it matters
- Which patients it is truly for (note this most often is not every patient!)
- What differentiates it from competitors
Positioning shapes how future data will be interpreted long before those data arrive. That is why positioning should not be viewed as a late-stage marketing exercise. It is a strategic capability that influences development, commercialization, and long-term franchise value across the product lifecycle.
Key Takeaways
- Start positioning early enough to influence development strategy
- Build positioning around future market needs, not just current assumptions
- Prioritize one defining idea rather than accumulating messages
- Treat positioning as a strategic discipline, not a late-stage commercialization exercise
- Use the DESIRE framework to pressure-test positioning: Is it Distinct, Emotive, Single-minded, Insight-led, Resonant, and Environment-aware?
How confident are you regarding your current or future brand’s positioning choices?
Take this 60 second pulse check to put your positioning to the test:
- DISTINCT – without the brand name, would customers still know it’s you, or could three competitors make the same claim?
- EMOTIVE – does your positioning move people, or just inform them? When an HCP or patient hears it, do they feel something that makes the brand matter?
- SINGLE-MINDED – if you had to defend one core idea your brand owns, what is it, and is everyone telling the same story?
- INSIGHT-LED – is your positioning built on a real, evidenced customer tension, or on what the bran team wishes were true?
- RESONANT – does it land with equal force across the audiences that decide your fate: HCPs, patients and payers, or only with one?
- ENVIRONMENT-AWARE – would it still hold up against the market three years out, with new entrants, shifting access, evolving standards or care?
If any of these gave you pause for thought, let’s talk.
